Properties of 3-(1-Phenyl-Propyl)-4-Oxycoumarin (Marcoumar®) in the Plasma when Tested in Normal Cases and under the Influence of Drugs

Summary

A fluorimetric method served to determine Marcoumar in blood plasma. The biological half-time of Marcoumar after an administration of 2.2 mg/10 kg is 6½ days. Variations in maintenance dose requirements seem not to be primarly determined by differences in absorption or excretion of the anticoagulant drug. In therapeutical concentrations about 99% of the drug are bound to plasma protein. Marcoumar can be displaced in vitro from plasma protein by different drugs. The anticoagulant effect is not increased in every case in which the anticoagulant is displaced in plasma from its protein binding.

• References

• 1 Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar [3-(l’-Phenyl-propyl)-4-oxy-cumarin] und seinen Antagonisten Konakion (synthetisches Vitamin K₁). Schweiz. med. Wschr. 1953; 83 (20) 471
• 2 Koller F, Jakob H. Über ein neues, hochaktives Antikoagulans mit protrahierter Wirkung (Marcoumar). Schweiz. med. Wschr. 1953; 83 (20) 476
• 3 Deutsch E, Hueber E.F, Mayer E, Wohlrab K. Über die Verwendung eines neuen Antikoagulans. Marcoumar, zur Therapie. Klin. Med. 1954; 2: 49
• 4 Hofstetter J. Bestimmungsmethode für Marcoumar in Blut-Plasma. Personal communication.
• 5 O’Reilly R.A, Aggeler P.M, Hoag M.S, Leong L. Studies on coumarin anticoagulant drugs: assay of warfarin and its biologic application. Thrombos. Diathes. haemorrh. (Stuttg.) 1962; 5: 82
• 6 Feigl F. Test through conversion into fluorescing alkali salt of o-hydroxycinnamic acid. J. Amer. chem. Soc. 1955; 77: 4162
• 7 Dettli L, Spring P. Pharmakokinetik der Chemotherapeutika: Theorie und Praxis. Regensburg. Jb. ärztl. Fortbild. 1966; 14: 17
• 8 Aggeler P. M, O’Reilly R. A. The pharmacological basis of oral anticoagulant therapy. In: Pathogenesis and Treatment of thromboembolic Diseases. Internat. Symposium Basle. ed Koller F, Duckert F, Streuli F, Schattauer F. K. Stuttgart 1965
• 9 Douglas A.S. Anticoagulant therapy. Blackwell Scientific Publications; Oxford: 1962
• 10 Anton A.H. The relation between the binding of sulfonamides to albumin and their antibacterial efficacy. J. Pharmacol. exp. Ther. 1960; 129: 282
• 11 Anton A.H. A drug-induced change in the distribution and renal excretion of sulfonamides. M. Pharmacol. exp. Therap. 1961; 134: 291
• 12 Newbould B.B, Kilpatrick R. Long-acting sulphonamides and protein-binding. Lancet 1960; I: 887
• 13 Aggeler P.M, O’Reilly R.A, Leong L, Kowitz P.E. Potentiation of anticoagulant effect of Warfarin by phenylbutazone. New Engl. J. Med. 1967; 276: 496
• 14 Ghristensen L.K, Hansen J.M, Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide treated diabetics. Lancet 1963; II: 1298
• 15 Kristensen M, Hansen J.M, Hellerup D. Potentiation of the tolbutamide effect by dicoumarol. Diabetes 1967; 16: 211
• 16 Thorp J.M. The influence of plasma proteins on the action of drugs. Absorption and Distribution of Drugs. Binns, T.B., E.S. Livingstone 1964